Global health R&D at work in Oregon
Portland State University (PSU) researchers have revived a once-potent malaria drug and created a company to move it forward. For many years, chloroquine was considered a miracle drug in treating malaria until the disease developed resistance. Rather than abandon it, PSU scientists reversed the resistance process with chemicals. This work led to a group of chloroquine hybrids and the birth of DesignMedix, a Portland start-up specializing in new approaches to fight infectious diseases. With funding from investors, the company provides opportunities for students and jobs for the region, highlighting the economic benefits of global health R&D.